The Serious Illness Care Program (SICP) is an evidence-based intervention designed to systemically implement serious illness conversations (SIC) into clinical practice. We previously piloted the SICP via telehealth for patients in the ambulatory setting. However, many patients with hematologic malignancies experience frequent hospitalizations, providing a key opportunity to conduct SICs in the inpatient setting. Assess the feasibility of an inpatient SICP and describe completion of advance directives and SIC documentation following SICP implementation. This was a single-arm pilot study including patients aged ³60 years with hematologic malignancies and their caregivers. Clinicians (advanced practitioners; hematology/oncology fellows) completed a 2-3-hour virtual training on the SICP. The primary outcome was feasibility (retention rate: % of consented patients who completed the SICP visit; >70% considered feasible). Secondary outcomes were advance directive completion health care proxy (HCP); Medical Order for Life Sustaining Treatment (MOLST) and documentation. We also collected data on advance care planning (ACP) engagement and disease understanding. We included 41 patients (mean age=68 years), 24 caregivers, and 22 clinicians; 38 SICP visits were completed (retention rate of 92.7%). The number of HCP and MOLST forms completed increased from 23 to 31 and from seven to 20 within one year of the SICP visits, respectively. All SICP visits were documented. ACP engagement numerically increased (p=0.24), and patients found the intervention to be acceptable. Patient estimates of life expectancy may have shifted after the SICP visit. The inpatient SICP was feasible, with potential increase in advance directive completion. NCT05433090.
LoCastro et al. (2026) studied this question.